Zacks Research Downgrades Milestone Pharmaceuticals (NASDAQ:MIST) to Hold

Milestone Pharmaceuticals (NASDAQ:MIST) was downgraded by research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report issued on Tuesday,Zacks.com reports.

A number of other research firms have also recently commented on MIST. Wells Fargo & Company upped their price target on Milestone Pharmaceuticals from $4.00 to $8.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a research note on Monday, December 29th. Wall Street Zen downgraded Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, January 10th. TD Cowen upgraded shares of Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, December 15th. Finally, HC Wainwright reissued a “buy” rating and set a $8.00 price target on shares of Milestone Pharmaceuticals in a research report on Tuesday, January 6th. Three analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Milestone Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $8.00.

Milestone Pharmaceuticals Price Performance

Milestone Pharmaceuticals stock opened at $1.73 on Tuesday. The company’s 50 day simple moving average is $1.93 and its 200-day simple moving average is $2.00. The company has a debt-to-equity ratio of 2.74, a quick ratio of 8.24 and a current ratio of 8.24. Milestone Pharmaceuticals has a 1 year low of $0.63 and a 1 year high of $3.06. The company has a market capitalization of $147.34 million, a price-to-earnings ratio of -2.11 and a beta of 0.46.

Insider Buying and Selling

In other Milestone Pharmaceuticals news, COO Jeffrey Edward Nelson sold 58,007 shares of the business’s stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $2.32, for a total transaction of $134,576.24. Following the completion of the transaction, the chief operating officer owned 41,993 shares in the company, valued at $97,423.76. The trade was a 58.01% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Joseph Oliveto sold 133,054 shares of the stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $2.32, for a total transaction of $308,685.28. Following the completion of the sale, the chief executive officer directly owned 450,667 shares in the company, valued at approximately $1,045,547.44. This represents a 22.79% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 416,327 shares of company stock valued at $935,458. Corporate insiders own 19.50% of the company’s stock.

Institutional Investors Weigh In On Milestone Pharmaceuticals

Several institutional investors have recently modified their holdings of the company. Propel Bio Management LLC increased its holdings in Milestone Pharmaceuticals by 186.1% in the third quarter. Propel Bio Management LLC now owns 5,124,890 shares of the company’s stock valued at $10,250,000 after buying an additional 3,333,333 shares during the last quarter. Orbimed Advisors LLC purchased a new stake in Milestone Pharmaceuticals during the 3rd quarter worth about $6,444,000. Simplify Asset Management Inc. boosted its position in shares of Milestone Pharmaceuticals by 186.2% during the 3rd quarter. Simplify Asset Management Inc. now owns 2,832,974 shares of the company’s stock worth $5,666,000 after acquiring an additional 1,842,974 shares in the last quarter. Marshall Wace LLP increased its holdings in shares of Milestone Pharmaceuticals by 289.8% in the 4th quarter. Marshall Wace LLP now owns 1,656,821 shares of the company’s stock valued at $3,347,000 after acquiring an additional 1,231,793 shares during the last quarter. Finally, Pathstone Holdings LLC acquired a new stake in shares of Milestone Pharmaceuticals during the 3rd quarter worth about $2,000,000. 86.18% of the stock is owned by hedge funds and other institutional investors.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.